Study guide

7.4 Quality Assurance Systems, Customer Complaints, and Product Recalls

PTCB Nonsterile Compounding Certificate Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Regulations, Standards, and Governance

1.1 Federal Regulations Framework (FD&C Act, DQSA, Sections 503A vs 503B) 1.2 USP Standards & Applicability (<795>, <800>, <1163>) 1.3 Personnel Roles, Training, and Hygiene Standards 1.4 Documentation, Master Formulation Records, and Compounding Records

2 Chapter 2: Facilities, Material Management, and Stability

2.1 Facilities, Environmental Controls, and Equipment 2.2 Material Sourcing, Component Selection & Inventory Controls 2.3 Beyond-Use Dates (BUDs), Stability & Packaging

3 Chapter 3: Nonsterile Dosage Forms & Formulations

3.1 Solid Dosage Forms & Compounding 3.2 Semisolid Dosage Forms 3.3 Liquid Dosage Forms 3.4 Specialized Topical & Transdermal Formulations

4 Chapter 4: Equipment, Utensils, and Processing Tools

4.1 Weighing and Volumetric Equipment 4.2 Mixing and Comminution Utensils

5 Chapter 5: Pharmaceutical Compounding Calculations

5.1 Weighing, Measuring, Aliquot Calculations, & Powder Volume Adjustments 5.2 Concentration, Alligation, Dilution, & Dosing Calculations

6 Chapter 6: Compounding Procedures, Garbing, and Hazardous Drug Safety

6.1 Garbing, Hand Hygiene, and Personal Protective Equipment for Nonsterile Compounding 6.2 Hazardous Drug Handling and USP <800> Compliance in Nonsterile Compounding 6.3 Packaging, Container-Closure Systems, Storage, and Quality Assurance

7 Chapter 7: Quality Assurance, Sanitation, and Risk Management

7.1 Cleaning, Sanitizing, and Facility Sanitation Protocols 7.2 Environmental Monitoring, Equipment Calibration, and Maintenance 7.3 Quality Control, Product Verification, and Release Testing 7.4 Quality Assurance Systems, Customer Complaints, and Product Recalls

7.4 Quality Assurance Systems, Customer Complaints, and Product Recalls

Key Takeaways Explain This Topic AI

QA is process-oriented and preventive; QC is planned, product-focused evidence used to decide whether specifications are met.

A serious complaint triggers patient protection, hold/quarantine of potentially affected units, preservation of evidence, scope assessment, and documented investigation.

Bulk drug substances under Section 503A require registered-establishment sourcing; other components require qualification against applicable monographs or documented specifications.

503B facilities have mandatory federal serious-adverse-event reporting duties; 503A pharmacies and state obligations follow different rules, so no universal 24–72 hour state timeline applies.

Class I means a reasonable probability that use or exposure will cause serious adverse health consequences or death; recall actions are risk-based and coordinated with applicable authorities.

Last updated: August 2026

7.4 Quality Assurance, Complaints, and Recalls

Quick Answer: QA prevents and detects system failures through SOPs, training, supplier and equipment controls, deviation review, CAPA, and trend analysis. A serious complaint triggers an immediate hold on potentially affected units, a documented investigation, risk-based communication, and any reporting or recall required by the facility, FDA status, and jurisdiction. Reporting timelines are not identical for a 503A pharmacy and a 503B outsourcing facility.

QA and QC Work Together

  • Attribute Quality Assurance Quality Control
  • Focus Processes and the overall quality system A specific component, preparation, or result

Examples SOPs, training, audits, vendor qualification, trend review, CAPA Inspection, pH, yield, assay, label and record checks

  • Purpose Prevent recurrence and maintain control Determine whether a specification is met
  • Timing Continuous Planned at appropriate process and release points

QC is product-focused, but it is not merely reactive; well-designed QC is planned into the master formulation.

Core Quality-System Controls

A nonsterile program includes:

SOP management: Controlled approval, access, revision, training, and review.

Personnel qualification: Initial training and competency before independent work, with reassessment at least every 12 months and after material changes or failures.

Component and supplier qualification: Bulk drug substances used under Section 503A meet statutory eligibility and come from FDA-registered establishments. Other components are evaluated against applicable monographs or documented specifications; registered-facility sourcing is recommended when possible.

Equipment and facility control: Cleaning, monitoring, maintenance, calibration/verification, and status labeling.

Deviation and change control: Document departures, assess impact, authorize disposition, and evaluate proposed changes before use.

Trend review: Analyze complaints, near misses, yields, environmental excursions, OOS results, and recurring equipment or training failures.

CAPA effectiveness: Confirm that corrective and preventive actions solved the root cause rather than merely closing paperwork.

Complaint Intake and Triage

Record who reported the complaint, patient and prescription identifiers, CNSP name/strength, lot or compounding-record identifier, dates, storage and use information, event or defect description, and any remaining product.

First protect the patient:

For a possible serious injury, overdose, contamination, wrong drug/strength, or route error, immediately involve the pharmacist/designated person and provide urgent clinical instructions through authorized personnel.

Place remaining affected units and related inventory on hold/quarantine so they cannot be dispensed.

Preserve returned product, packaging, records, component lots, and relevant electronic data.

Determine whether the potential scope extends to other patients, lots, formulations, equipment, or components.

Do not destroy evidence before the investigation and disposition are documented.

Investigation and CAPA

Compare the complaint with the prescription, MFR, CR, calculations, component CoAs, equipment status, cleaning records, storage data, label, and distribution history. Test a returned or retained sample when a suitable method and sample are available.

Use a structured root-cause method such as 5 Whys or a fishbone diagram. Distinguish:

Correction/containment: Stop dispensing, replace product, correct the immediate record.

Corrective action: Remove the cause of the detected failure.

Preventive/system action: Reduce recurrence elsewhere.

Effectiveness check: Verify later data show the action worked.

A technician supports evidence gathering and documentation within role; the designated person or authorized quality/release authority approves final disposition.

Adverse-Event and Regulatory Reporting

FDA MedWatch accepts voluntary reports from healthcare professionals and consumers about serious adverse events and product-quality problems. A traditional 503A pharmacy does not acquire the 503B mandatory reporting rule merely because it compounds.

A registered 503B outsourcing facility has federal adverse-event reporting duties, including initial serious-adverse-event reporting within 15 calendar days under the applicable FDA requirements. State boards, health departments, malpractice carriers, prescribers, and other authorities may impose additional duties. Check the actual jurisdiction; there is no universal “most states require 24–72 hours” rule.

Recall Classification

FDA classifies recalls by health hazard:

Class FDA meaning

Class I Reasonable probability that use of or exposure to the violative product will cause serious adverse health consequences or death

Class II Use or exposure may cause temporary or medically reversible adverse health consequences, or the probability of serious consequences is remote

Class III Use or exposure is not likely to cause adverse health consequences

A tenfold clonidine concentration dispensed to children can warrant Class I treatment because serious harm or death is reasonably probable. Final FDA classification and recall coordination are regulatory functions; the pharmacy should not delay immediate patient protection while waiting for a formal class.

Recall Execution

The written recall procedure addresses:

Decision and scope: Identify affected prescription/lot records, components, dates, and distribution.

Stop and quarantine: Block dispensing and isolate on-hand units.

Distribution trace: Produce a complete patient, prescriber, clinic, and shipment list.

Communication: Send clear risk-based instructions through appropriate channels, including whether to stop use and how to obtain replacement or care.

Regulatory coordination: Notify FDA and state authorities when applicable and follow their instructions.

Effectiveness checks: Confirm recipients received and acted on the notice.

Reconciliation: Account for returned, destroyed, and unreachable units.

Disposition and CAPA: Dispose under drug, controlled-substance, hazardous-waste, and environmental rules; complete investigation, CAPA, and effectiveness review.

Notification urgency follows the risk. A Class I-type hazard may require rapid calls and electronic outreach, not reliance on certified mail alone.

Exam Decision Pattern

For a serious complaint, choose hold/quarantine and investigate . For federal reporting, distinguish 503A voluntary MedWatch pathways from 503B mandatory duties. For Class I, look for reasonable probability of serious harm or death.

  • Customer Complaint, CAPA, and Product Recall Workflow Complaint / Defect / Adverse Event
  • │
  • ▼
  • Protect patient + hold/quarantine + preserve evidence
  • │
  • ▼
  • Trace scope → investigate → risk assess
  • │
  • ├── Reporting/recall required → notify, recover, effectiveness checks
  • └── No recall → documented disposition
  • │
  • ▼
  • CAPA + effectiveness review + trend monitoring